BTAVF:OTC-BATM Advanced Communications Ltd (USD)

COMMON STOCK | Medical Instruments & Supplies | OTC

Last Closing Price

USD 1.52

Change

0.00 (0.00)%

Market Cap

USD 0.60B

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BATM Advanced Communications Ltd., together with its subsidiaries, provides real-time technologies for networking solutions and bio-medical systems in Israel, the United States, and Europe. It operates in two divisions, Networking and Cyber, and Bio-Medical. The Networking and Cyber division is involved in the research and development, production, and marketing of data communication products, including network function virtualization in the fields of local and wide area networks, and premises management systems. This division provides ICT solutions and services; and cyber security solutions. It also offers software services, such as training, technical support and maintenance related to the communication products, mobile and Web solutions, UI, UX design, branding, graphical design, and drivers and embedded solutions; and construction contracts. The Bio-Medical division engages in the research and development, production, marketing, and distribution of medical products, such as laboratory diagnostics and sterilization equipment. This division offers molecular biology diagnostics; provides solutions to treat pathogenic and medical waste in laboratories and hospitals, as well as for pharmaceutical manufacturing plants and agricultural applications; and distributes diagnostic equipment and medical supplies of various brands. BATM Advanced Communications Ltd. has a collaboration with Novamed Ltd for the joint development and marketing of a home-use testing kit for COVID-19. The company was founded in 1992 and is headquartered in Hod Hasharon, Israel.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-26 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ESLOY EssilorLuxottica Société ano..

N/A

USD55.26B 46.33 25.84
ESLOF EssilorLuxottica Société ano..

N/A

USD54.01B 46.12 25.84
HOCPY HOYA Corporation

N/A

USD41.33B 39.71 0.22
HOCPF HOYA Corporation

N/A

USD40.58B 39.63 0.22
CLPBY Coloplast A/S

N/A

USD32.46B 53.59 5.68
CLPBF Coloplast A/S

N/A

USD32.37B 53.46 5.64
TRUMF Terumo Corporation

N/A

USD29.81B 40.88 0.30
SDMHF Sartorius Stedim Biotech S.A

N/A

USD29.70B 104.98 66.54
TRUMY Terumo Corporation

N/A

USD29.59B 41.13 0.30
OCPNY Olympus Corporation

N/A

USD25.16B 70.53 0.20

ETFs Containing BTAVF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 310.30% 91% A- 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 310.30% 91% A- 93% A
Trailing 12 Months  
Capital Gain 310.30% 92% A- 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 310.30% 92% A- 94% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 59.83% N/A N/A 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 59.83% N/A N/A 82% B-
Risk Return Profile  
Volatility (Standard Deviation) 127.19% N/A N/A 22% F
Risk Adjusted Return 47.04% N/A N/A 82% B-
Market Capitalization 0.60B 55% F 68% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 127.19 16% F 5% F
Price/Book Ratio 5.82 51% F 21% F
Price / Cash Flow Ratio 83.58 4% F 2% F
EV/EBITDA 50.06 18% F 6% F
Management Effectiveness  
Return on Equity 5.37% 38% F 60% D-
Return on Invested Capital -2.43% 31% F 34% F
Return on Assets -0.33% 49% F 51% F
Debt to Equity Ratio 0.70% 72% C- 78% C+
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.38 66% D 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector